A recent survey commissioned by Roche has revealed a concerning trend: millennials are at the highest risk of missing crucial cervical cancer screenings. This generation, aged 29 to 42, is more likely to skip or postpone their appointments compared to any other age group. In fact, nearly a third of European millennials eligible for routine cervical screening have already missed out on this vital health check. But here's where it gets controversial: despite the availability of free or heavily subsidized screening services, millennials face unique challenges that push cervical screenings to the back burner.
The research, conducted by GWI across six European countries, surveyed 5,518 internet users aged 16 to 64. It found that millennials, often referred to as the 'have it all generation,' are struggling to balance their careers, caregiving responsibilities, and relationships. These overlapping commitments seem to take precedence over their own health, resulting in higher rates of missed or delayed cervical screenings. Joanna Sickler, Vice-President of Health Policy and External Affairs at Roche Diagnostics, highlights the emotional, logistical, and societal pressures that millennials face, which disproportionately affect their ability to prioritize cervical screening.
"It's critical to design solutions that fit into their reality," Sickler emphasizes. "Self-sampling, for example, could be a game-changer, allowing millennials to take control of their health without disrupting their busy lives."
Professor Daniel Kelly OBE, Co-Chair of the HPV and Hep B Action Network at the European Cancer Organisation, agrees that healthcare systems must adapt. "We need to offer flexible, person-centred screening options and access to vaccination. It's about meeting women where they are and fostering open dialogue and community engagement to normalize cervical health as a shared responsibility."
Fear is a significant barrier to cervical screening attendance. Thirty percent of women cite fear as the primary reason for missing or delaying their appointments, driven by anxiety about discomfort, pain, or potential results. Professional commitments and workplace demands are also major factors, with high-income earners being 22% more likely to delay appointments due to workplace pressures. Caregiving responsibilities, particularly for parents, add another layer of complexity, with 27% of surveyed parents reporting delayed or canceled cervical screening appointments.
The lack of awareness and discussion around cervical screening compounds these challenges. Half of the surveyed women believe there are no support or subsidy schemes for healthcare appointments, and nearly 50% of respondents, including 43% of millennials, admitted they had never spoken about cervical screening. This cultural discomfort leaves many without the emotional support needed to prioritize their health.
Practical and emotional support are key to improving attendance rates. Among millennials who postponed their screenings, 12% said assistance with travel or childcare would motivate them, while 19% emphasized the need for greater workplace flexibility and encouragement from employers. Emotional support from family, friends, or colleagues was also cited as a potential motivator by 10% of respondents.
Cervical cancer is one of the most preventable cancers, with almost all cases avoidable through vaccination and regular screenings. Yet, every year, it affects more than 600,000 women globally. At Roche Diagnostics, we are committed to eliminating cervical cancer through collective action. Our campaign, "Cervical cancer: it only ends with all of us," aims to reduce barriers to access, normalize conversations about cervical health, and encourage more eligible individuals to attend their routine screenings.
Roche is working with healthcare systems, governments, and communities to provide flexible screening options, such as self-collection, and to promote inclusive education and clear communication about the importance of early detection. Together, we can empower individuals to take control of their health and prevent cervical cancer from claiming more lives. Eliminating cervical cancer truly starts with all of us.
For more information and to join the conversation, visit https://roche.com/stories/cervical-cancer-it-only-ends-with-all-of-us.
About Roche:
Founded in 1896, Roche has grown from a small Swiss company to become the world's largest biotechnology firm and the global leader in in-vitro diagnostics. We are dedicated to scientific excellence and discovering innovative medicines and diagnostics to improve and save lives worldwide. Our commitment to personalized healthcare and our partnerships with stakeholders allow us to transform healthcare delivery and have a greater impact.
Recognized for our long-term perspective, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for fifteen consecutive years. This distinction reflects our efforts to improve access to healthcare in collaboration with local partners in every country we operate.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
